Literature DB >> 12804566

High levels of urinary midkine in various cancer patients.

Shinya Ikematsu1, Kohji Okamoto, Yoshihiro Yoshida, Munehiro Oda, Hitomi Sugano-Nagano, Kinya Ashida, Hideshi Kumai, Kenji Kadomatsu, Hisako Muramatsu, Sadatoshi Sakuma.   

Abstract

Midkine (MK) is a heparin-binding growth factor, which promotes growth, migration, and survival of various cells, and MK expression is increased in many human carcinomas. We determined the urinary MK level by enzyme-linked immunoassay. Taking 311pg/mg creatinine as a cut-off level, 70% of patients with various carcinomas (n=142) gave positive values, while only 5.5% of healthy volunteers (n=330) did. In case of gastric carcinoma, 17 out of 21 patients with stage 1 tumor were positive. Urinary MK levels are expected to become a convenient marker as an aid in detection of tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804566     DOI: 10.1016/s0006-291x(03)00984-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

2.  Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.

Authors:  Fan Zhang; Junjun Wang; Xiaoyong Zheng; Lijuan Hu; Jie Chen; Feng Jiang; Yumin Wang
Journal:  J Clin Lab Anal       Date:  2018-05-23       Impact factor: 2.352

3.  Efficacy of urinary midkine as a biomarker in patients with acute kidney injury.

Authors:  Hiroki Hayashi; Waichi Sato; Tomoki Kosugi; Kunihiro Nishimura; Daisuke Sugiyama; Naoko Asano; Shinya Ikematsu; Kimihiro Komori; Kimitoshi Nishiwaki; Kenji Kadomatsu; Seiichi Matsuo; Shoichi Maruyama; Yukio Yuzawa
Journal:  Clin Exp Nephrol       Date:  2016-08-16       Impact factor: 2.801

4.  Expression of midkine and its clinical significance in esophageal squamous cell carcinoma.

Authors:  Ying-Jia Ren; Qing-Yun Zhang
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 5.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 6.  Lessons from the heart and ischemic limbs: midkine as anti-inflammatory mediator for kidney diseases?

Authors:  Delia Lidia Şalaru; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-12-04       Impact factor: 2.370

7.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 8.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

9.  Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma.

Authors:  N J Shimwell; R T Bryan; W Wei; N D James; K K Cheng; M P Zeegers; P J Johnson; A Martin; D G Ward
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

10.  Clinical significance of midkine expression in pancreatic head carcinoma.

Authors:  S Maeda; H Shinchi; H Kurahara; Y Mataki; H Noma; K Maemura; K Aridome; T Yokomine; S Natsugoe; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.